For example, CD28, CD40, and TNFRSF4 (OX40) antagonists are in early stage clinical trials for treatment of various immune disorders, whereas CD28, CD40, and TNFRSF4 (OX40) agonists are in early stage clinical trials for various cancer indications (Table 10). This evidence concerns the gene CD40 and immune system disorder.